Remove 2018 Remove Clinic Remove Disease Remove Radiation
article thumbnail

Cardiac PET use increases in coronary artery disease

AuntMinnie

PET, CT, and MRI use for assessing coronary artery disease increased in Medicare patients from 2018 to 2022, while SPECT and stress echocardiography declined over the same period, researchers have reported. Taken together, these findings call for efforts to address barriers impeding wider uptake of PET,” the group wrote.

Disease 89
article thumbnail

Multi-Institutional Study Data Presented at ASTRO 2023 Builds Upon Growing Evidence of GammaTile for Patients with Brain Tumors

Imaging Technology

2 poster presentation at the American Society for Radiation Oncology's (ASTRO) 65th Annual Meeting, ASTRO 2023 , being held this week in San Diego, CA. sites were treated with GammaTile, a treatment that provides immediate radiation where it is needed most after brain tumor removal surgery.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Terran Biosciences Receives FDA Clearance for NM-101, the Industry’s First Software for the analysis of Neuromelanin-sensitive MRI

Imaging Technology

We believe this technology could become very important in the clinical workflow of patients with neurological and psychiatric disorders.” While neuromelanin was first described in the 19 th century, researchers have elucidated its possible role as a biomarker for neurological disorders such as Parkinson’s disease in the last two decades.

article thumbnail

Blue Earth Diagnostics Announces Addition of POSLUMA (Flotufolastat F 18) Injection to NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer

Imaging Technology

We believe it further validates the clinical utility of POSLUMA in patients with newly diagnosed or recurrent prostate cancer, and can help expand patient access. FDA, as well as on the Phase 3 clinical trial results published recently in the Journal of Urology and European Urology. Chief Executive Officer of the Company. “We

article thumbnail

The rise of theranostics: Part 1 -- Gaining momentum

AuntMinnie

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. After binding to the receptor, the drug works by entering the cell allowing radiation to cause damage to the tumor cells.

article thumbnail

The rise of theranostics: Part 1 -- Gaining momentum

AuntMinnie

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. After binding to the receptor, the drug works by entering the cell allowing radiation to cause damage to the tumor cells.

article thumbnail

U.S. FDA Approves Blue Earth Diagnostics’ POSLUMA (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer

Imaging Technology

All of us at Blue Earth Diagnostics want to express our sincere gratitude to the many patients, physicians, clinical trial sites and collaborators who have worked closely with us to progress POSLUMA.” In clinical trials , the safety of POSLUMA was evaluated in 747 patients with initial or recurrent prostate cancer.